Invitro Fertilization
Conditions
Brief summary
Induction of ovulation cycle: 1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu. 2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration 3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of HCG trigger. 4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection 5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as luteal support from the day of oocytes retrieval. 6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization. 7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks after, to confirm fetal pulsations as well as number of gestational sacs (clinical pregnancy). 8. The implantation rate is calculated as the number of viable embryos divided by the number of transferred embryos multiplied by 100
Detailed description
Induction of ovulation cycle: 1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu. 2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration 3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of HCG trigger. 4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection 5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as luteal support from the day of oocytes retrieval. 6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization. 7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks after, to confirm fetal pulsations as well as number of gestational sacs (clinical pregnancy). 8. The implantation rate is calculated as the number of viable embryos divided by the number of transferred embryos multiplied by 100
Interventions
DRUGGonadotropins
1\) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
DRUGGNRH antagonist
cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
DRUGHuman chorionic gonadotropin Chorimon
10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
Sponsors
Cairo University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 44 Years
Healthy volunteers
No
Inclusion criteria
* 4- Poor responder according to ESHRE consensus; in which at least 2 of the following should be present: Advanced maternal age (≥ 40 years old) or any other risk factor A previous poor ovarian response (cycles cancelled or ≤ 3 oocytes with a conventional protocol)An abnormal ovarian reserve test (ORT); antral follicle count (AFC) \< 5-7 follicles or anti-mullerian hormone (AMH) ≤0.5- 1.1 ng/ml In the absence of advanced maternal age or abnormal ORT, two previous episodes of poor ovarian response after maximal stimulation patients are also considered poor responders according to ESHRE consensus. Presence and Adequate visualization of both ovaries Uterine cavity within normal anatomy assessed with HSG, hysteroscopy and TVUS
Exclusion criteria
Any factor which may affect reproductive outcome other than that the patient is a poor responder will be excluded from the study, like: 1. Severe male factor . 2. Uterine factor (eg: fibroid, polyp, Ashermann, .. etc) 3. Immunological disorder (eg: SLE, APS, … etc) 4. Thyroid or adrenal dysfunction 5. Neoplasia (especially: hypothalamic, pit, ovarian) 6. Women diagnosed with PCOS according to Rotterdam criteria 7. Hydrosalpinx that hasn't been surgically removed or ligated. 8. Untreated hyperprolactinemia 9. Abnormal bleeding disorder 10. Hepatic or renal dysfunction 11. Hypersenstivity to study medication ( GNRH antagonist) 12. Need to take medication that can influence ovarian stimulation 13. Endometriosis grade 3 or 4 14. Ovarian cyst\> 10 cm.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical pregnancy rate | 4 weeks after HCG triggering | appearance of intrauterine gestational sac by transvaginal ultrasound |
Countries
Egypt
Contacts
Primary ContactAhmed Maged, MD
Backup ContactRadwa Fahmy, MD
Outcome results
None listed